Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“MedCity is invaluable among the many sources of industry reporting because the team endeavor to bring the truly new, and innovative opportunities and developments to light.”

Ken Kirby, President, Transdermal Delivery Solutions Corp


Sign up for our daily newsletter


Salix expands drug delivery technology partnership with Indian pharma

1:26 pm by | 0 Comments

Salix Pharmaceuticals is extending an agreement with an Indian pharmaceutical partner to give Salix exclusive global rights, except for India, to a key drug-delivery technology.

Morrisville, North Carolina-based Salix (NASDAQ:SLXP) in 2009 licensed the drug delivery technology from Mumbai, India-based Lupin Pharmaceuticals. Salix uses that technology in its gastrointestinal drug rifaximin, marketed as Xifaxan. Salix announced Wednesday that Lupin has now granted Salix exclusive worldwide rights, outside India, to use that technology and any technology jointly developed by the companies for all rifaximin products for human use.

The 2009 pact gave Salix only U.S. rights to the technology, which allowed for the development of an extended release rifaximin product. At that time, the only U.S. Food and Drug Administration-approved indication for the rifaximin was treating traveler’s diarrhea. Rifaximin is a gut-selective antibiotic with broad spectrum activity against a range of pathogens.

Advertisement

Salix has since been looking to add to the number of indications for the drug. The company last year received approval on rifaximin for treating hepatic encephalopathy, a brain disorder associated with severe liver disease. Salix has also been seeking to add  nonconstipation irritable bowel syndrome as a new indication. The FDA in March informed the company it could not approve that application in its current form and Salix said it would meet with FDA officials before determining its next steps.

With the new agreement, Salix must now make a $10 million up-front payment to Lupin. Additional payments could come if the company hits U.S. regulatory milestones for products covered by either Lupin patents or patents jointly held by the companies. Salix must also pay royalties on any sales, as well as quarterly payments for product development.

Enhanced by Zemanta

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

By Frank Vinluan

Frank Vinluan is the North Carolina Bureau Chief for MedCity News.
More posts by Author

0 comments

Hear the latest news first

Get our daily newsletter or follow us.

 

Advertisement